Reported 12 months ago
On July 1, 2024, The News Brigade reported that the National Health Insurance Administration Director Chih-Liang Shih estimated a potential savings of NT$270 million in drug costs through a trial project encouraging the use of biosimilar drugs. The initiative aims to increase the substitution rate of designated biosimilar drugs to 30% from the current 7% over three years, incentivizing physicians to prescribe drugs for diseases like ankylosing spondylitis and other conditions. By promoting biosimilar drug usage, it is expected to optimize resource allocation and facilitate the introduction of more new drugs to benefit patients.
Source: YAHOO